W Henry Boom

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/364155/publications.pdf

Version: 2024-02-01

68 papers	6,077 citations	94381 37 h-index	95218 68 g-index
70 all docs	70 docs citations	70 times ranked	6456 citing authors

#	Article	IF	Citations
1	Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane Î²-Lactamase Inhibitor To Augment Î²-Lactam Action. MBio, 2022, 13, e0352921.	1.8	13
2	Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies. EBioMedicine, 2022, 76, 103839.	2.7	19
3	Monocyte Transcriptional Responses to Mycobacterium tuberculosis Associate with Resistance to Tuberculin Skin Test and Interferon Gamma Release Assay Conversion. MSphere, 2022, 7, .	1.3	8
4	Methylome-wide Analysis Reveals Epigenetic Marks Associated With Resistance to Tuberculosis in Human Immunodeficiency Virusâ€"Infected Individuals From East Africa. Journal of Infectious Diseases, 2021, 224, 695-704.	1.9	1
5	The knowns and unknowns of latent Mycobacterium tuberculosis infection. Journal of Clinical Investigation, 2021, 131, .	3.9	67
6	The Pup-Proteasome System Protects Mycobacteria from Antimicrobial Antifolates. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	3
7	HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection. Tuberculosis, 2021, 127, 102062.	0.8	11
8	â€œOne-Two Punchâ€• Synergistic ÃŸ-Lactam Combinations forMycobacterium abscessusand Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clinical Infectious Diseases, 2021, 73, 1532-1536.	2.9	15
9	Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-Î³ release assay conversion. Journal of Clinical Investigation, 2021, 131, .	3.9	13
10	Interaction between M. tuberculosis Lineage and Human Genetic Variants Reveals Novel Pathway Associations with Severity of TB. Pathogens, 2021, 10, 1487.	1.2	5
11	Resistance to TST/IGRA conversion in Uganda: Heritability and Genome-Wide Association Study. EBioMedicine, 2021, 74, 103727.	2.7	9
12	Importance of Study Design and Phenotype Definition in Ongoing Studies of Resistance to Latent Mycobacterium tuberculosis Infection. Journal of Infectious Diseases, 2020, 221, 1025-1026.	1.9	5
13	Insights into the <scp>l</scp> , <scp>d</scp> -Transpeptidases and <scp>d</scp> , <scp>d</scp> -Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	22
14	Interaction between host genes and Mycobacterium tuberculosis lineage can affect tuberculosis severity: Evidence for coevolution?. PLoS Genetics, 2020, 16, e1008728.	1.5	40
15	Genetic variability and consequence of Mycobacterium tuberculosis lineage 3 in Kampala-Uganda. PLoS ONE, 2019, 14, e0221644.	1.1	10
16	IFN-Î³-independent immune markers of Mycobacterium tuberculosis exposure. Nature Medicine, 2019, 25, 977-987.	15.2	186
17	MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria. Journal of Immunology, 2019, 203, 2917-2927.	0.4	55
18	Long-term Stability of Resistance to Latent Mycobacterium tuberculosis Infection in Highly Exposed Tuberculosis Household Contacts in Kampala, Uganda. Clinical Infectious Diseases, 2019, 68, 1705-1712.	2.9	46

#	Article	IF	Citations
19	Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy. ACS Infectious Diseases, 2019, 5, 353-364.	1.8	9
20	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1198-1208.	2.5	217
21	Resistance and Susceptibility to Mycobacterium tuberculosis Infection and Disease in Tuberculosis Households in Kampala, Uganda. American Journal of Epidemiology, 2018, 187, 1477-1489.	1.6	69
22	Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respiratory Medicine,the, 2018, 6, 276-286.	5.2	23
23	Bacterial Factors That Predict Relapse after Tuberculosis Therapy. New England Journal of Medicine, 2018, 379, 823-833.	13.9	114
24	Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nature Reviews Immunology, 2018, 18, 575-589.	10.6	241
25	Mycobacterium tuberculosis Membrane Vesicles Inhibit T Cell Activation. Journal of Immunology, 2017, 198, 2028-2037.	0.4	66
26	Proteomics and Network Analyses Reveal Inhibition of Aktâ€mTOR Signaling in CD4⁺ T Cells by Mycobacterium tuberculosis Mannoseâ€Capped Lipoarabinomannan. Proteomics, 2017, 17, 1700233.	1.3	10
27	Toll like Receptor 2 engagement on CD4⁺ T cells promotes TH9 differentiation and function. European Journal of Immunology, 2017, 47, 1513-1524.	1.6	31
28	Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection. PLoS ONE, 2017, 12, e0175844.	1.1	64
29	Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathogens, 2017, 13, e1006687.	2.1	193
30	Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 6591-6599.	1.4	19
31	Bacillus Calmetteâ€"GuÃ©rin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses. Journal of Immunology, 2016, 197, 1100-1110.	0.4	121
32	Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nature Genetics, 2016, 48, 1535-1543.	9.4	326
33	Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis inÂvitro and in whole blood culture. Tuberculosis, 2016, 98, 92-96.	0.8	17
34	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, The, 2016, 387, 2312-2322.	6.3	678
35	Mannose-Capped Lipoarabinomannan from Mycobacterium tuberculosis Induces CD4+ T Cell Anergy via GRAIL. Journal of Immunology, 2016, 196, 691-702.	0.4	35
36	A single-nucleotide-polymorphism real-time PCR assay for genotyping of Mycobacterium tuberculosis complex in peri-urban Kampala. BMC Infectious Diseases, 2015, 15, 396.	1.3	5

#	Article	IF	Citations
37	Proteomic and bioinformatics profile of paired human alveolar macrophages and peripheral blood monocytes. Proteomics, 2015, 15, 3797-3805.	1.3	15
38	Polymorphisms in TICAM2 and IL1B are associated with TB. Genes and Immunity, 2015, 16, 127-133.	2.2	49
39	Comparison of MGIT and Myco/F Lytic Liquid-Based Blood Culture Systems for Recovery of Mycobacterium tuberculosis from Pleural Fluid. Journal of Clinical Microbiology, 2015, 53, 1391-1394.	1.8	10
40	A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis, 2015, 95, 713-721.	0.8	35
41	Incubation time of Mycobacterium tuberculosis complex sputum cultures in BACTEC MGIT 960: 4weeks of negative culture is enough for physicians to consider alternative diagnoses. Diagnostic Microbiology and Infectious Disease, 2015, 83, 162-164.	0.8	9
42	Bacterial Membrane Vesicles Mediate the Release of Mycobacterium tuberculosis Lipoglycans and Lipoproteins from Infected Macrophages. Journal of Immunology, 2015, 195, 1044-1053.	0.4	107
43	Toll-Like Receptor 2-Dependent Extracellular Signal-Regulated Kinase Signaling in Mycobacterium tuberculosis-Infected Macrophages Drives Anti-Inflammatory Responses and Inhibits Th1 Polarization of Responding T Cells. Infection and Immunity, 2015, 83, 2242-2254.	1.0	94
44	Regulation of mammalian siderophore 2,5-DHBA in the innate immune response to infection. Journal of Experimental Medicine, 2014, 211, 1197-1213.	4.2	64
45	Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine, 2014, 32, 3982-3988.	1.7	33
46	How we determined the most reliable solid medium for studying treatment of tuberculosis. Tuberculosis, 2014, 94, 317-322.	0.8	5
47	Effect of Isoniazid Therapy for Latent TB Infection on QuantiFERON-TB Gold In-Tube Responses in Adults With Positive Tuberculin Skin Test Results in a High TB Incidence Area. Chest, 2014, 145, 612-617.	0.4	37
48	Tuberculin Skin Test Reversion following Isoniazid Preventive Therapy Reflects Diversity of Immune Response to Primary Mycobacterium tuberculosis Infection. PLoS ONE, 2014, 9, e96613.	1.1	13
49	Longitudinal Changes in CD4+ T-Cell Memory Responses Induced by BCG Vaccination of Newborns. Journal of Infectious Diseases, 2013, 207, 1084-1094.	1.9	120
50	Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa. PLoS ONE, 2013, 8, e74080.	1.1	48
51	Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation. Cellular Immunology, 2012, 275, 98-105.	1.4	58
52	Mycobacterium tuberculosis Lipoproteins Directly Regulate Human Memory CD4 ⁺ T Cell Activation via Toll-Like Receptors 1 and 2. Infection and Immunity, 2011, 79, 663-673.	1.0	69
53	Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2. Nature Structural and Molecular Biology, 2010, 17, 1088-1095.	3.6	122
54	Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nature Reviews Microbiology, 2010, 8, 296-307.	13.6	349

#	Article	IF	Citations
55	Mycobacterium tuberculosisSynergizes with ATP To Induce Release of Microvesicles and Exosomes Containing Major Histocompatibility Complex Class II Molecules Capable of Antigen Presentation. Infection and Immunity, 2010, 78, 5116-5125.	1.0	102
56	Mycobacterium tuberculosisCell Wall Glycolipids Directly Inhibit CD4⁺T-Cell Activation by Interfering with Proximal T-Cell-Receptor Signaling. Infection and Immunity, 2009, 77, 4574-4583.	1.0	46
57	Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection. Cellular Immunology, 2009, 254, 94-104.	1.4	53
58	TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cellular Immunology, 2009, 258, 29-37.	1.4	137
59	CCAAT/Enhancer-Binding Protein Î² and Î´ Binding to CIITA Promoters Is Associated with the Inhibition of CIITA Expression in Response toMycobacterium tuberculosis19-kDa Lipoprotein. Journal of Immunology, 2007, 179, 6910-6918.	0.4	66
60	Mycobacterium tuberculosis19-kDa Lipoprotein Inhibits IFN-Î³-Induced Chromatin Remodeling ofMHC2TAby TLR2 and MAPK Signaling. Journal of Immunology, 2006, 176, 4323-4330.	0.4	198
61	Mycobacterium tuberculosis LprA Is a Lipoprotein Agonist of TLR2 That Regulates Innate Immunity and APC Function. Journal of Immunology, 2006, 177, 422-429.	0.4	203
62	Mycobacterium tuberculosisLprG (Rv1411c): A Novel TLR-2 Ligand That Inhibits Human Macrophage Class II MHC Antigen Processing. Journal of Immunology, 2004, 173, 2660-2668.	0.4	231
63	Prolonged Toll-Like Receptor Signaling by Mycobacterium tuberculosis and Its 19-Kilodalton Lipoprotein Inhibits Gamma Interferon-Induced Regulation of Selected Genes in Macrophages. Infection and Immunity, 2004, 72, 6603-6614.	1.0	150
64	Inhibition of Major Histocompatibility Complex II Expression and Antigen Processing in Murine Alveolar Macrophages by Mycobacterium bovis BCG and the 19-Kilodalton Mycobacterial Lipoprotein. Infection and Immunity, 2004, 72, 2101-2110.	1.0	100
65	Inhibition of IFN-Î³-Induced Class II Transactivator Expression by a 19-kDa Lipoprotein fromMycobacterium tuberculosis: A Potential Mechanism for Immune Evasion. Journal of Immunology, 2003, 171, 175-184.	0.4	226
66	Processing of Mycobacterium tuberculosis Antigen 85B Involves Intraphagosomal Formation of Peptideâ€“Major Histocompatibility Complex II Complexes and Is Inhibited by Live Bacilli that Decrease Phagosome Maturation. Journal of Experimental Medicine, 2001, 194, 1421-1432.	4.2	121
67	Toll-Like Receptor 2-Dependent Inhibition of Macrophage Class II MHC Expression and Antigen Processing by 19-kDa Lipoprotein ofMycobacterium tuberculosis. Journal of Immunology, 2001, 167, 910-918.	0.4	391
68	Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. Immunological Reviews, 1999, 168, 217-239.	2.8	47